Clinical trials: Mammary Tumor
Breast Cancer, Breast Neoplasms, Endometrial Cancer, Endometrial Neoplasm
GEN1047 for Solid Tumors - First in Human (FIH) Trial
The purpose of this trial is to measure the following in participants with solid tumors who receive GEN1047: The side effects seen with GEN1047 What the body does with GEN1047 once it is administered What GEN1047 does to the body…
- Conditions
- Breast Cancer, Breast Neoplasms, Endometrial Cancer, Endometrial Neoplasm, Ovarian Cancer, Ovarian Neoplasms, Squamous Non Small Cell Lung Cancer (NSCLC-SCC)
- Trial name
- NCT05180474
- Testing
- GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive tumor cells.
- Where
- 36 sites in United States, Belgium and 7 more
- Volunteers
- 179 people
- Sponsor
- Genmab
Breast Cancer Female, Postoperative Pain
Study of Lipid Mediators in Chronic Postoperative Pain - LICP
This interventional prospective study aims firstly to investigate variations in lipid levels in blood samples and their potential relationship with the duration and/or intensity of post-operative pain.
- Trial name
- LICP (NCT06907810)
- Testing
- Blood sample + questionnaire
- Where
- Belgium
- Volunteers
- 300 people
- Sponsor
- Université Catholique de Louvain
Early Stage Breast Carcinoma
Stereotactic Image-Guided Neoadjuvant Ablative Radiation Then Lumpectomy
Radiation therapy after surgery to remove breast cancer improves control of the breast cancer. Standard therapy after breast conservation surgery is five to six weeks of radiation to the entire breast.
- Trial name
- SIGNAL 2 (NCT02212860)
- Testing
- Stereotactic Body Radiation Then Surgery
- Where
- Canada
- Volunteers
- 139 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Solid Tumor, Adult, BRCA1 Mutation
Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors
The purpose of this study is to determine if the experimental treatment with poly-ADP ribose polymerase (PARP) inhibitor, ACE-86225106 is safe, tolerable and has anti-cancer activity in adult patients with advanced solid tumors.
- Conditions
- Solid Tumor, Adult, BRCA1 Mutation, BRCA2 Mutation, Ovarian Cancer
- Trial name
- NCT06380660
- Testing
- ACE-86225106 tablet
- Where
- 14 sites in China
- Volunteers
- 298 people
- Sponsor
- Acerand Therapeutics (Shanghai) Limited
Axillary Web Syndrome
Effects of Rehabilitation and Kinesio Taping to Prevent Axillary Web Syndrome After Breast Cancer Surgery
Axillary web syndrome (AWS) is a complication associated with breast cancer surgery, characterized by pain, functional limitation of the shoulder and decreased quality of life.
- Trial name
- NCT06269523
- Testing
- Kinesio taping, Lymphatic drainage, Lymphatic drainage
- Where
- Italy
- Volunteers
- 18 people
- Sponsor
- University of Palermo
Breast Neoplasms, Neoplasm Metastasis
Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast Cancer
This study is a prospective, multicenter, phase II randomized clinical trial. It is planned to enroll 60 patients with advanced HER2 negative breast cancer, who will be randomly assigned to the experimental group and the control…
- Conditions
- Breast Neoplasms, Neoplasm Metastasis, Drug Therapy, Bevacizumab
- Trial name
- NCT06539559
- Testing
- Eribulin, Bevacizumab
- Where
- 3 sites in China
- Volunteers
- 60 people
- Sponsor
- Wang Jiayu
Breast Carcinoma, Cardiomyopathy
TRPC6 Characterization to Predict and Prevent Chemotherapy Related Cardiomyopathy and Heart Failure With Breast Cancer
This study examines TRPC6 in predicting and preventing chemotherapy related cardiac toxicity and heart failure in patients with breast cancer.
- Conditions
- Breast Carcinoma, Cardiomyopathy, Congestive Heart Failure
- Trial name
- NCT05507879
- Testing
- Biospecimen Collection, Electronic Medical Record
- Where
- 2 sites in United States
- Volunteers
- 200 people
- Sponsor
- Mayo Clinic
Metastatic Breast Cancer
Vinorelbine Oral Plus Capecitabine Combination In Metastatic Breast Cancer
This study will evaluate the toxicity and secondary the efficacy of the combination vinorelbine plus capecitabine in metastatic breast cancer patients
- Trial name
- NCT00706069
- Testing
- Vinorelbine oral, Capecitabine
- Where
- 4 sites in Greece
- Volunteers
- 40 people
- Sponsor
- Hellenic Oncology Research Group
Breast Cancer
Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer
Millennium has developed TAK-228, which is a novel, highly selective, orally bioavailable adenosine 5' triphosphate (ATP)-competitive inhibitor of the serine/threonine kinase referred to as the mechanistic target of rapamycin…
- Trial name
- NCT02619669
- Testing
- TAK-228, Letrozole
- Where
- United States
- Sponsor
- Gary Schwartz
Breast Cancer
Fujifilm Feature Comparison Reader Study to Compare Old vs New Processing
The purpose of the feature comparison study is to evaluate general mammographic features in images of the same breast when reconstructed with modified (ISR and DVIIm) processing as compared to the original processing (FBP with…
- Trial name
- NCT03586583
- Testing
- FBP, ISR
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Fujifilm Medical Systems USA, Inc.
Metastatic Triple Negative Breast Cancer
Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer
This study will investigate the safety and efficacy of TIL therapy in patients with metastatic TNBC who have progressed on at least one and no more than three prior systemic anticancer therapies.
- Trial name
- NCT04111510
- Testing
- Tumor infiltrating lymphocytes (TIL) LN-145
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Yale University
Breast Neoplasms
Identification of Breast Cancer Specific Markers in Patients Compared to Healthy Participants
This is an exploratory research study with the aim of identifying specific cancer biomarkers in various subtypes of breast cancer.
- Trial name
- NCT05054010
- Where
- Italy
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Tethis S.p.A.
Breast Cancer
Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Letrozole may fight breast cancer by lowering the amount of estrogen the body makes.
- Trial name
- SOLE (NCT00553410)
- Testing
- Letrozole
- Where
- 164 sites in United States, Australia and 18 more
- Volunteers
- 4,884 people
- Sponsor
- ETOP IBCSG Partners Foundation
Breast Cancer, Psychosocial Effects of Cancer and Its Treatment
Stress Reduction in Older Women With Stage II, Stage III, or Stage IV Breast Cancer
RATIONALE: Transcendental meditation may be an effective way to decrease the amount of stress in older women with breast cancer.
- Trial name
- NCT00006346
- Testing
- psychosocial assessment and care, quality-of-life assessment
- Where
- 3 sites in United States
- Sponsor
- Unity Health Toronto
Breast Cancer
Pyrotinib After Trastuzumab-based Adjuvant Therapy in Patients With HER2-positive Breast Cancer
This trial is a multicenter, open-label, phase II trial conducted at 23 centers in China. High-risk HER2 positive patients receive pyrotinib 400mg/day for one year or half year for extented adjuvant therapy.
- Trial name
- NCT05880927
- Testing
- Pyrotinib
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Taizhou Hospital
Breast Cancer
Comparing 5 and 15 Fractions for Whole Breast Irradiation After Breast Conserving Surgery
Adjuvant radiotherapy after breast-conserving surgery for breast cancer reduces the risk of locoregional relapse and ensures better overall survival.
- Trial name
- YO-HAI5 (NCT03677427)
- Testing
- Radiation
- Where
- Belgium
- Volunteers
- 488 people
- Sponsor
- University Hospital, Ghent
Breast Cancer
Utilizing Social Contacts to Facilitate Mammogram Screening Among African American Women
Eliminating racial disparities in breast cancer is a top public health priority. African American (AA) women often present with more advanced and aggressive disease at the time of diagnosis and are more likely to die from breast…
- Trial name
- NCT05275361
- Testing
- Social Contact Reminder
- Where
- United States
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Breast Neoplasms
First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting.
This is a prospective, single-arm, multi-center observational non-interventional study (NIS) in Germany and Austria.
- Trial name
- PERFORM (NCT04767594)
- Testing
- Palbociclib + endocrine therapy
- Where
- 192 sites in Austria, Germany
- Volunteers
- 1,407 people
- Sponsor
- Pfizer
Invasive Breast Cancer
Therapy for Locally Advanced Breast Cancer Using Doxil, Paclitaxel, and Cyclophosphamide With Avastin
This study will evaluate the rate of pathological complete response (pCR) to the sequential therapy of Doxil, paclitaxel, and cyclophosphamide with concurrent Avastin for patients with locally advanced invasive (T2,T3, Nany, M0)…
- Trial name
- NCT00635050
- Testing
- Doxil, Paclitaxel, Cyclophosphamide, Avastin
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Alabama at Birmingham
HER2 + Breast Cancer
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of HLX319 vs. EU-Phesgo® in the Neoadjuvant Therapy of HER2-Positive Early or Locally Advanced Breast Cancer
This is a study to compare the similarity in Pharmacokinetics (PK) profile of HLX319 vs. EU-Phesgo® in patients with HER2-positive early or locally advanced breast cancer .
- Trial name
- NCT07601620
- Testing
- HLX319, EU-Phesgo®
- Volunteers
- 258 people
- Sponsor
- Shanghai Henlius Biotech
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.